Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AXSM | INST-CLUSTER | bearish | 4/10 | Three institutional asset managers trimmed or exited AXSM positions in Q3 2026, led by Assenagon Asset Management reduci | Oct 20, 2026 |
| CDXS | INST-CLUSTER | bearish | 4/10 | Three institutional asset managers reduced or nearly exited their positions in Codexis during Q3 2026, with aggregate ne | Oct 20, 2026 |
| HALO | INST-CLUSTER | bullish | 4/10 | Five institutional asset managers accumulated $277.5M in HALO during Q3 2026, led by Congress Asset Management ($155.7M | Oct 20, 2026 |
| INSM | INST-CLUSTER | bullish | 4/10 | A bullish institutional cluster emerged in INSM during Q3 2026, with 5 asset managers adding or doubling positions total | Oct 20, 2026 |
| INDV | INST-CLUSTER | bullish | 4/10 | Four asset managers, led by Assenagon Asset Management, doubled their INDV positions in Q3 2026, adding a combined $65.6 | Oct 20, 2026 |
| EXEL | INST-CLUSTER | neutral | 2/10 | Four small asset managers accumulated $5.8M in new EXEL positions during Q3 2026, while one larger manager trimmed $15.6 | Oct 20, 2026 |
| INDP | 8-K | bearish | 6/10 | Indaptus Therapeutics completed its previously announced private placement on October 16, 2026, issuing 20,338,974 share | Oct 20, 2026 |
| LKFT | 6-K | neutral | 2/10 | Lakefront Biotherapeutics completed its share repurchase program, buying back 107,804 shares for ~€2.85 million between | Oct 20, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined ~$479K in open-market sales over a 7-day window, with Rothblatt | Oct 20, 2026 |
| LFCR | 8-K | neutral | 3/10 | Lifecore Biomedical set November 4, 2026 as the record date for a special meeting to vote on its pending merger with Haz | Oct 20, 2026 |
| BNTC | DEFA14A | neutral | 2/10 | Benitec Biopharma filed a DEFA14A notice of internet availability of proxy materials for its December 3, 2026 annual mee | Oct 20, 2026 |
| BNTC | DEF 14A | neutral | 4/10 | Benitec Biopharma filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held on Decembe | Oct 20, 2026 |
| AVXL | 8-K | neutral | 4/10 | Anavex announced completion of clinical conduct for two blarcamesine pharmacology studies (ADME and DDI) in healthy volu | Oct 20, 2026 |
| TOVX | DEF 14A | bearish | 5/10 | Theriva Biologics is holding a special meeting on November 18, 2026, to seek stockholder approval for three proposals: ( | Oct 20, 2026 |
| PURE | 8-K | bearish | 5/10 | Pure Bioscience raised $555,000 in a private placement, issuing 10,183,486 shares at $0.0545 per share to director Tom Y | Oct 20, 2026 |
| NBTX | 6-K | neutral | 1/10 | Nanobiotix filed a Form 6-K with a press release disclosing its share capital and voting rights as of September 30, 2026 | Oct 20, 2026 |
| TRAW | DEFA14A | neutral | 3/10 | Traws Pharma filed a DEFA14A (definitive additional proxy soliciting material) to provide a notice of internet availabil | Oct 20, 2026 |
| VRTX | 8-K | neutral | 2/10 | Vertex Pharmaceuticals appointed Daniel Brennan, former CFO of Boston Scientific, to its board of directors on October 2 | Oct 20, 2026 |
| TPST | DEFA14A | neutral | 4/10 | Tempest Therapeutics filed a DEFA14A (definitive additional proxy soliciting materials) reporting that its reconvened sp | Oct 20, 2026 |
| TKNO | 424B5 | bearish | 6/10 | Alpha Teknova filed a preliminary prospectus supplement for an underwritten public offering of common stock. The offerin | Oct 20, 2026 |
| TPST | 8-K | neutral | 3/10 | Tempest Therapeutics adjourned its reconvened special meeting of stockholders on October 14, 2026, because it lacked suf | Oct 20, 2026 |
| TRAW | DEF 14A | bearish | 6/10 | Traws Pharma is holding a special meeting on December 3, 2026 to seek stockholder approval for a reverse stock split (1- | Oct 20, 2026 |
| TRAX | 8-K | neutral | 2/10 | First Tracks Biotherapeutics closed a private placement of 6,106,870 shares of common stock on October 19, 2026, and ent | Oct 20, 2026 |
| TKNO | PRESS-RELEASE | bearish | 5/10 | Alpha Teknova has announced an underwritten public offering of its common stock, with an additional 15% option for under | Oct 20, 2026 |
| TKNO | PRESS-RELEASE | mixed | 6/10 | Alpha Teknova pre-announced preliminary Q3 2026 revenue of $12.5M-$12.7M (up 19-21% YoY) and gross margin expansion of 5 | Oct 20, 2026 |
| PLUR | 8-K | bearish | 5/10 | Pluri Inc. issued 833,334 common shares at $1.50/share and a warrant for 833,334 shares at $1.65/share to its chairman a | Oct 20, 2026 |
| AVXL | PRESS-RELEASE | neutral | 3/10 | Anavex provided a corporate update on blarcamesine across three CNS indications. Clinical conduct was completed for DDI | Oct 20, 2026 |
| SCNI | 6-K | neutral | 4/10 | Scinai CEO issued a shareholder letter detailing a $5.1M committed CDMO agreement, a $5.3M combined net financing, and a | Oct 20, 2026 |
| ONCY | 8-K | neutral | 3/10 | Oncolytics Biotech announced a trial-in-progress abstract and e-poster for its REO 033 study of pelareorep in RAS-mutant | Oct 20, 2026 |
| ONCY | PRESS-RELEASE | neutral | 4/10 | Oncolytics Biotech presented a trial-in-progress abstract at ESMO 2026 for REO 033, a randomized Phase 2 study of pelare | Oct 20, 2026 |